Latvija - latviešu - Zāļu valsts aģentūra

baxter latvia, sia, latvia - ciklofosfamīds - apvalkotā tablete - 50 mg

Latvija - latviešu - Zāļu valsts aģentūra

baxter latvia, sia, latvia - ciklofosfamīds - pulveris injekciju šķīduma pagatavošanai - 200 mg

Latvija - latviešu - Zāļu valsts aģentūra

baxter latvia, sia, latvia - ciklofosfamīds - pulveris injekciju šķīduma pagatavošanai - 500 mg

Latvija - latviešu - Zāļu valsts aģentūra

baxter latvia, sia, latvia - ciklofosfamīds - pulveris injekciju šķīduma pagatavošanai - 1 g

Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - ciklofosfamīds - pulveris injekciju/infūziju šķīduma pagatavošanai - 500 mg

Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - ciklofosfamīds - pulveris injekciju/infūziju šķīduma pagatavošanai - 1000 mg

Latvija - latviešu - Zāļu valsts aģentūra

baxter sas, france - ciklofosfamīds - apvalkotā tablete - 50 mg

Latvija - latviešu - Zāļu valsts aģentūra

baxter sas, france - ciklofosfamīds - apvalkotā tablete - 50 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis; microscopic polyangiitis; pemphigus - antineoplastiski līdzekļi - rixathon is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)rixathon is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. rixathon monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. rixathon is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). hroniskas limfocītu leikēmija (cll)rixathon kombinācijā ar ķīmijterapiju, ir indicēts, lai ārstētu pacientus ar iepriekš neārstētiem un relapsed/ugunsizturīgi hronisku limfocītu leikēmija. ir pieejami visai ierobežoti dati par efektivitāti un drošību pacientiem, kas iepriekš ārstēti ar monoklonālo antivielu tostarp rituksimabs vai pacientiem, ugunsizturīgas, lai iepriekšējā rituksimabs plus ķīmijterapiju. skatīt nodaĝā 5. 1, lai iegūtu papildu informāciju. reimatoīdais arthritisrixathon kombinācijā ar metotreksātu ir indicēts, lai ārstētu pieaugušiem pacientiem ar smagu aktīvu reimatoīdo artrītu, kas ir bijusi neatbilstoša atbildreakcija vai neiecietību pret citiem slimību modificējošiem pretreimatisma zāles (dmard), tostarp viens vai vairāki audzēju nekrozes faktoru (tnf) inhibitoru terapiju. rituksimabs ir pierādīts, lai samazinātu likmi, locītavu bojājumu progresēšanu, mērot ar x-ray un uzlabot fizisko funkciju, ja to lieto kopā ar metotreksātu. granulomatosis with polyangiitis and microscopic polyangiitisrixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). rixathon, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisrixathon is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastiski līdzekļi - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ir pieejami visai ierobežoti dati par efektivitāti un drošību pacientiem, kas iepriekš ārstēti ar monoklonālo antivielu tostarp rituksimabs vai pacientiem, ugunsizturīgas, lai iepriekšējā rituksimabs plus ķīmijterapiju. skatīt nodaĝā 5. 1, lai iegūtu papildu informāciju. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimabs ir pierādīts, lai samazinātu likmi, locītavu bojājumu progresēšanu, mērot ar x-ray un uzlabot fizisko funkciju, ja to lieto kopā ar metotreksātu. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).